Early detection makes prostate and colorectal cancers among the most survivable cancers, yet both continue to claim lives, particularly when underlying biological drivers are poorly understood. This project examines how chronic oxidative stress contributes to cancer progression by focusing on a specific group of antioxidant enzymes, the peroxiredoxins, which influence genetic stability, cell migration, and tumor growth. Research activities center on two cancers. In prostate cancer, the study investigates how peroxiredoxins PRDX3 and PRDX4 interact with FKBP52, a regulator of androgen receptor signaling, using gene-knockout approaches to assess their roles in disease progression. In colorectal cancer, the work builds on preliminary findings showing that PRDX4 is expressed differently in cancer cells and in tissue samples from early-onset Hispanic patients compared with non-Hispanic White patients. By clarifying how PRDX4 shapes colorectal cancer progression, particularly in Hispanic populations, the project aims to identify biological mechanisms that contribute to cancer disparities. Results may inform new strategies for early detection, screening, and targeted treatment, aiming to improve survival outcomes and reduce inequities in cancer care.